International journal of clinical and experimental pathology最新文献

{"title":"Evaluation of the efficacy and safety of toripalimab combination therapy for treatment of advanced gastric cancer: a meta-analysis.","authors":"Xinlin Yu, Ran Cui, Ping Guo","doi":"10.62347/GZOW5960","DOIUrl":"https://doi.org/10.62347/GZOW5960","url":null,"abstract":"<p><strong>Background: </strong>To systematically evaluate the efficacy and safety of combination therapy with toripalimab in the treatment of advanced gastric cancer (GC).</p><p><strong>Methods: </strong>We conducted a thorough search for relevant studies in PubMed, Embase, Cochrane Library, and Web of Science. Effect estimates were computed utilizing Stata software (version 14.0) and either random or fixed effects models, as applicable. A subgroup analysis was undertaken to assess the effect of various combination therapies on overall response rate (ORR). Begg and Egger's tests were employed to assess publication bias.</p><p><strong>Results: </strong>The study consisted of 8 trials, which included 277 participants with advanced gastric cancer. The overall ORR was 41.4% (95% CI, 32.4%-50.3%), with a disease control rate (DCR) of 83.6% (95% CI, 74.6%-92.7%), a median overall survival (mOS) of 11.0 months (95% CI, 9.6-12.4), and a median progression-free survival (mPFS) of 4.2 months (95% CI, 2.5-6.0) for the combination therapy with toripalimab. Subgroup analysis revealed that the combination of toripalimab and chemotherapy achieved a greater ORR compared to the non-chemotherapy group, with ORR rates of 49.8% (95% CI, 42.2%-57.4%) and 31.9% (95% CI, 26.7%-37.1%), respectively. The combination therapy with toripalimab led to adverse events (AEs) of any grade at 94.0% of cases (95% CI, 89.5%-98.5%) and grade 3 AEs at 32.4% (95% CI, 17.8%-47.1%). The sensitivity analysis indicated that no single study affected the overall results.</p><p><strong>Conclusions: </strong>Combination therapy of toripalimab can improve clinical efficacy, although with increased but manageable toxicity. Additional clinical trials are required to assess comprehensively the efficacy and safety of alternative toripalimab regimens. The review agreement has been recorded with PROSPERO (CRD42024585696).</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 3","pages":"96-109"},"PeriodicalIF":1.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a glycolysis-associated lncRNA signature to predict survival of patients with colorectal cancer.","authors":"Gaoceng Zhu, Yutian Kang, Mei Luo, Linling Ju, Yajun Sun, Lin Chen","doi":"10.62347/RVLY4737","DOIUrl":"https://doi.org/10.62347/RVLY4737","url":null,"abstract":"<p><strong>Objective: </strong>Colorectal cancer (CRC) still has a poor prognosis and is one of the most common malignancies worldwide. Recently, a close correlation between glycolysis and the progression of CRC has been reported. Hence, explorations of the prognostic value of glycolysis-associated long noncoding RNAs in CRC patients are urgently needed. This study aimed to investigate the role of glycolysis-associated lncRNAs for predicting the prognosis and treatment response of CRC, thereby identifying more biomarkers for CRC.</p><p><strong>Methods: </strong>RNA sequencing (RNA-seq) data for CRC from The Cancer Genome Atlas database were used. A glycolysis-associated long noncoding RNA (lncRNA) signature was estimated by Cox regression analysis, and its predictive capacity was assessed by constructing a receiver operating characteristic (ROC) curve and performing a gene set enrichment analysis.</p><p><strong>Results: </strong>One of our constructed glycolysis-related clusters was strongly correlated with an immunosuppressive tumor environment. Moreover, a signature consisting of 14 glycolysis-associated lncRNAs was used as a prognostic model, and CRC patients were classified into a low-risk group and a high-risk group based on the average risk score of this signature. In addition, the low-risk group experienced longer overall survival (OS) than the high-risk group. The area under the ROC curve (AUC) validated the sensitivity and specificity of the signature. The signature was identified as an individual element and was closely related to the progression of CRC. Finally, two glycolysis-associated lncRNAs, namely, TNFRSF10A-AS1 and ZKSCAN2-DT, were further clinically verified to effectively predict the prognosis of CRC patients.</p><p><strong>Conclusion: </strong>Glycolysis-associated lncRNAs may be employed as prognostic and therapeutic biomarkers for CRC.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 3","pages":"110-122"},"PeriodicalIF":1.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: NKD1 down-regulation is associated with poor prognosis in breast invasive ductal carcinoma.","authors":"Zhi-Dong Lv, Lin Zhang, Xiang-Ping Liu, Li-Ying Jin, Qian Dong, Fu-Nian Li, Hai-Bo Wang, Bin Kong","doi":"10.62347/BKQJ1119","DOIUrl":"https://doi.org/10.62347/BKQJ1119","url":null,"abstract":"<p><p>[This corrects the article on p. 4015 in vol. 8, PMID: 26097589.].</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 3","pages":"128-129"},"PeriodicalIF":1.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collision tumor of low grade endometrial stromal sarcoma and cervical squamous cell carcinoma: a case report.","authors":"Xuxuan Zhang, Xiao Tang","doi":"10.62347/FWIW8283","DOIUrl":"https://doi.org/10.62347/FWIW8283","url":null,"abstract":"<p><p>Uterine collision tumor is a rare pathologic type composed of two or more malignant tumors, with cervical collision tumors being even rarer. The mechanism of occurrence of collision tumors is not clear. We hope to help clinicians and pathologists understand and diagnose this condition. We report a case of a 53-year-old female diagnosed with poorly differentiated squamous cell carcinoma of the cervix through biopsy. After reviewing previous reports on collision tumors in different locations and theiry types in the cervix and uterus, we found that collisions between cervical squamous cell carcinoma and low-grade endometrial stromal sarcoma were rare. Identifying this type of collision tumor may help with future diagnosis and treatment.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 3","pages":"123-127"},"PeriodicalIF":1.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequencing of high-frequency mutated genes in breast cancer (BRCA) and associated-functions analysis.","authors":"Xuelian Li, Mei Yang, Liyuan Yang, Xuefei Dang, Xueqing Li, Gang Li","doi":"10.62347/YODE5431","DOIUrl":"10.62347/YODE5431","url":null,"abstract":"<p><strong>Objective: </strong>Mutations or aberrant expression of genes in an organism tend not to be completely random and this cumulative effect predisposes to the development of malignant tumours. This study aims to reveal the possible aberrant expression of high frequency mutated genes, and then to investigate their role in development, prognosis, signalling pathway function and drug resistance in breast cancer.</p><p><strong>Methods: </strong>The mutated genes in breast cancer (BRCA) clinical samples were identified and detected by high-throughput sequencing. High-frequency mutant genes were counted. Gene expression profiles and the relationship with prognosis were analysed throughout TCGA database. qRT-PCR was used to analyse the mRNA levels of the six high-frequency mutant genes in BRCA tissues and cell lines. IHC was used to analyse the protein levels of the six high-frequency mutant genes in BRCA tissues. The linear interaction, single-cell layer clustering status and the influence in immune cell infiltration degree among these six high-frequency mutant genes were analysed by bioinformatics analysis. The STITCH and cMAP datasets were used for high-frequency mutant gene interaction networks, association signalling pathway enrichment and drug-transcriptome analyses. The effects of trastuzumab on the proliferative capacity of breast cancer cells, as well as on the expression of six high-frequency mutated genes were determined by CCK8 assay.</p><p><strong>Results: </strong>The genes that were statistically found to have high-frequency mutations in the samples recruited in the present study by high-throughput sequencing analysis included TP53, PIK3CA, NF1, TBX3, BRCA1 and BRCA2. The expression profiles of these genes and the correlation with prognosis were further demonstrated using the TCGA database: the trend in this study was similar to that of BRCA in TCGA. The mRNA and protein expression of these genes showed that the expression of TP53, NF1, TBX3, BRCA1 and BRCA2 was higher in tumor samples than that in normal samples, with an opposite trend for PIK3CA, a similar trend was observed in BRCA cell lines. The protein expressions of TP53, NF1, TBX3, BRCA1 and BRCA2 displayed the same trend by IHC. Other correlation results include 1) the single cell layer clustering of these six genes resulted in significant clustering with few overlapping regions; 2) these six genes showed different degrees of influence on BRCA immune cell infiltration; 3) these six genes showed a significant correlation between each other; 4) the network of each gene had partially overlapping molecules; and 5) the PI3K pathway was a key association pathway in BRCA. Finally, the cell proliferation ability results confirmed the optimal concentration of trastuzumab and its effect on mRNA expression of these six genes.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 2","pages":"46-62"},"PeriodicalIF":1.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive low-grade papillary urothelial carcinoma with whorled features: a report of two cases.","authors":"Kiran Madwani, Pramila Moideen, Michael P Toscano, Lakshmi K Vemavarapu, Trent D Trzpuc, Suash J Sharma","doi":"10.62347/DFQO7724","DOIUrl":"10.62347/DFQO7724","url":null,"abstract":"<p><p>Non-invasive papillary urothelial carcinomas present as cytoarchitectural disorders without invasion through the basement membrane. They are divided into low-grade and high-grade categories on the basis of the extent of cytologic atypia and architectural disarray. Notably, divergent differentiation (such as squamous and glandular differentiation) and variants (such as nested, micropapillary, plasmacytoid, and sarcomatoid) are reported primarily in invasive and high-grade urothelial carcinomas. We present two cases of low-grade non-invasive papillary urothelial carcinoma with recently described whorled features (urothelial eddies). Both patients were 77-year-old males with small papillary lesions in the bladder. Histopathologic examination revealed low-grade non-invasive papillary urothelial carcinoma with a sporadic whorled pattern. Patient number 1's tumor exhibited cytokeratin (CK) 20 immunopositivity, up to 5% Ki-67 labeling, and wild-type p53 staining. Patient number 2's tumor was negative for CK20 with wild type p53 staining in portions with whorls, but demonstrated diffuse CK20 and extensive p53 staining (possible mutation) in tumor portions lacking whorls. Patient number 1 experienced a 14-month recurrence and a second possible recurrence 43 months after the initial diagnosis. Patient number 2 experienced recurrence of low-grade papillary urothelial carcinoma with focal whorls in one location and subsequently a distinct low-grade papillary urothelial carcinoma with whorled features in a different part of the bladder. Our limited study supports the reported association of rare whorled features with non-invasive low-grade papillary urothelial carcinoma, albeit with a diverse immunophenotype. Evaluation of both whorled and non-whorled areas in the histology along with CK20 and p53 staining may be helpful for complete diagnostic and prognostic evaluation of these cases.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 2","pages":"89-95"},"PeriodicalIF":1.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ploidy status analysis in small cell lung cancer cells and its use in cytopathological diagnosis.","authors":"Shiyin He, Jiamin Zhang, Tao Wan, Hongli Deng, Dairong Li","doi":"10.62347/UINT5317","DOIUrl":"10.62347/UINT5317","url":null,"abstract":"<p><strong>Objective: </strong>To explore the characteristics of the ploidy status of Small Cell Lung Cancer (SCLC) cells and assesses its efficacy in cytopathological diagnosis of SCLC.</p><p><strong>Methods: </strong>A retrospective analysis was performed on patients who agreed to DNA image cytometry (DNA ICM) and serum tumor biomarker testing. Samples for ploidy assessment, all from bronchial procedures, were analyzed using DNA ICM. Data on demographic features, pathological characteristics, staging results, biomarkers such as neuron specific enolase (NSE) and Pro-gastrin-releasing peptide (ProGRP) data, and ploidy status across different groups were collected. Corresponding statistical analyses were conducted to examine differences in aneuploid status among the groups. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic efficacy of DNA ICM and tumor markers for diagnosing SCLC.</p><p><strong>Results: </strong>A total of 74 patients with SCLC, 108 patients with NSCLC, and 74 patients with benign lesions were included. The age range of all patients was 26 to 85 years, with 69% being male and 31% female. In terms of ploidy status, single aneuploid cell peaks and double aneuploid peaks were observed in both SCLC and NSCLC groups. The proportions of two types of aneuploid cell peaks differed significantly between the two groups (<i>P</i>=0.008). The aneuploid cell ratio showed a high accuracy for small-cell lung cancer, with a sensitivity of 91.2% and a specificity of 88.1%. There was no statistical difference in ploidy status between limited and extensive stages of SCLC. As for biomarkers, the AUC (area under the curve) values were 0.921 for NSE and 0.928 for ProGRP, with a significant difference in NSE between two stages of SCLC (<i>P</i>=0.015), while no significant difference was observed in ProGRP.</p><p><strong>Conclusion: </strong>Aneuploid cell peaks in SCLC patients are mostly distributed in the near triploid range, possibly serving as a specific cytological marker for SCLC. DNA ICM is a highly sensitive tool that may be an adjunct for SCLC diagnosis.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 2","pages":"77-88"},"PeriodicalIF":1.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of machine learning application for the identification of lipid metabolism-associated diagnostic model in ischemic stroke.","authors":"Xiangtian Meng, Runping Xu, Haoheng Wang, Junle Zhu, Jingliang Ye, Chun Luo","doi":"10.62347/BDIP4409","DOIUrl":"10.62347/BDIP4409","url":null,"abstract":"<p><strong>Introduction: </strong>Ischemic Stroke (IS) is characterized by complex molecular alterations involving disruptions in lipid metabolism and immune interactions. However, the roles of lipid metabolism-associated genes in the pathogenesis of IS through immune regulation interaction are rarely explored. In this study, we aimed to explore the intricate correlation between lipid metabolism-associated immune changes and IS through a machine-learning algorithm.</p><p><strong>Materials and methods: </strong>We downloaded the GSE16561, GSE22255, and GSE37587 datasets from NCBI. Using the GSE16561 dataset, we analyzed differential gene expression profiles related to lipid metabolism with the \"Limma\" R package. We constructed a diagnostic model employing techniques such as Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression and Random Forest (RF), which was further validated using the independent GSE22255 and GSE37587 datasets. Correlations between model genes and immune cell percentages were examined by Spearman analysis. We further validated the diagnostic value of these model genes in 28 clinical samples using RT-qPCR.</p><p><strong>Results: </strong>We identified 26 lipid metabolism genes with significant expression disparities between normal and diseased groups, closely linked to immune cell populations. Seven signature genes (ACSS1, ADSL, CYP27A1, MTF1, SOAT1, STAT3, and SUMF2) were identified using LASSO and RF algorithms for a potential diagnostic model, effectively distinguishing healthy and IS samples in both training and validation (AUC = 0.725) datasets. The mRNA expression levels of these model genes were further validated as a blood biomarker for IS patients in our clinical samples. Single-cell analysis further revealed high expression of Cyp27a1 in dendritic cells and macrophages, and decreasing expression of Soat in progenitor cells as the disease progressed. The expression of Stat3 in most immune cells was upregulated in progenitor cells as the disease progressed. Additionally, a regulatory network identified transcription factors regulating genes such as STAT3.</p><p><strong>Conclusion: </strong>This study identified novel lipid metabolism biomarkers for IS, enhancing our understanding of IS by shedding light on lipid metabolism and immune interactions. This may facilitate innovative diagnostic approaches to IS.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 2","pages":"63-76"},"PeriodicalIF":1.1,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer.","authors":"Haoyue Hu, Min Min, Hongchun Dai, Youpan Tang, Jun He","doi":"10.62347/XWHW6190","DOIUrl":"10.62347/XWHW6190","url":null,"abstract":"<p><p>Targeted therapies are effective in non-small cell lung cancer (NSCLC) patients with driver gene mutations. Chemotherapy combined with immunotherapy is also a common treatment strategy in lung cancer. However, in previous studies, patients with ALK (Anaplastic Lymphoma Kinase) rearranged had a low response to immune checkpoint inhibitor (ICI) and the role of immunotherapy in ALK-positive NSCLC patients is unclear. Here, we report a case of a young man with ALK rearranged who demonstrated a complete response to anti-PD1 combination with chemotherapy, which suggests some ALK-rearranged patients with high expression of PD-L1 may permanently benefit from immunotherapy.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 1","pages":"37-41"},"PeriodicalIF":1.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of ABCB1 gene polymorphisms with aspirin or clopidogrel resistance in ischemic stroke: a meta-analysis.","authors":"Junjie Lv, Aiqin Chen, Chang Xu, Gaofeng Shao, Mingfei Zhao","doi":"10.62347/IBGQ2413","DOIUrl":"10.62347/IBGQ2413","url":null,"abstract":"<p><strong>Objective: </strong>Ischemic stroke (IS) is a major public health concern worldwide. In this study, we aimed to investigate the relationship between <i>ABCB1</i> gene polymorphisms and antiplatelet resistance in patients with IS.</p><p><strong>Methods: </strong>We performed a comprehensive search of the PubMed, China National Knowledge Infrastructure, Web of Science, and WANFANG databases for articles published until February 2024. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the association between <i>ABCB1</i> polymorphisms and antiplatelet resistance in patients with IS. All the statistical analyses were performed using STATA version 11.0.</p><p><strong>Results: </strong>Eleven studies containing 2,228 cases and 2,556 controls met the inclusion criteria. Our results showed that aspirin resistance in patients with IS was significantly correlated with the polymorphism of <i>ABCB1</i> rs1045642 (Allele model: OR=1.5, 95% CI [1.10, 2.05], P=0.010; Homozygote model: OR=2.02, 95% CI [1.01, 4.05], P=0.047; Heterozygote model: OR=1.37, 95% CI [0.91, 2.08], P=0.132; Dominant model: OR=1.75, 95% CI [1.09, 2.81], P=0.021; Recessive model: OR=1.61, 95% CI [1.01, 2.57], P=0.045). Meanwhile, we found that <i>ABCB1</i> rs1045642 polymorphism might be significantly associated with clopidogrel resistance in IS (A. Homozygote model: OR=3.35, 95% CI [1.99, 5.63], P=0.000; B. Heterozygote model: OR=0.81, 95% CI [0.54, 1.21], P=0.895; C. Dominant model: OR=1.41, 95% CI [0.59, 3.36], P=0.435; D. Recessive model: OR=3.43, 95% CI [2.14, 5.51], P=0.000).</p><p><strong>Conclusion: </strong>This meta-analysis suggests a potential link between <i>ABCB1</i> rs1045642 polymorphism and resistance to clopidogrel or aspirin in patients with IS.</p>","PeriodicalId":13943,"journal":{"name":"International journal of clinical and experimental pathology","volume":"18 1","pages":"1-11"},"PeriodicalIF":1.1,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}